Q-omics provides the consensus-scored FBXO17 profile across patient tissues and cancer cell-line models. FBXO17 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FBXO17 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, FBXO17 RNA expression shows 16,187 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where FBXO17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO17 survival associations across molecular data types. FBXO17 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO17 RNA expression–survival associations across cancer types. High FBXO17 expression shows unfavorable associations in MESO, STAD, LGG and THCA, but favorable associations in UVM and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FBXO17 RNA expression.
This table summarizes FBXO17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO17 shows lower tumor expression in KICH, THCA, UCEC and BRCA and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher FBXO17 RNA expression in tumor versus normal tissue (log2 FC = +1.852, t-test p < 0.001).
This table shows molecular features associated with FBXO17 in patient tissues and cancer cell lines. In patient samples, FBXO17 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
